文献速递血栓与止血

先天性易栓症与肺栓塞患者预后的关联

Association between congenital thrombophilia and outcomes in pulmonary embolism patients.
PubMed 文献 · Blood Adv · 2020-01-01

一项前瞻性观察研究纳入436例连续肺栓塞患者,检测蛋白C、蛋白S、抗凝血酶III、因子V Leiden和凝血酶原G20210A突变。先天性易栓症患病率为7.1%,首次发作年龄≤50岁和男性是其独立预测因素,但先天性易栓症与抗凝治疗下的复发或死亡风险无关。

要点

  • 肺栓塞患者中先天性易栓症患病率为7.1%,以蛋白C和蛋白S缺陷为主。
  • 首次发作年龄≤50岁和男性是先天性易栓症的独立预测因素。
  • 先天性易栓症与抗凝治疗下死亡或复发性静脉血栓栓塞复合结局风险无关。

核心结论

  • 年龄≤50岁和男性与肺栓塞患者先天性易栓症的发生独立相关。
  • 先天性易栓症与抗凝治疗下的复发或死亡风险无关。

研究设计与样本

  • 前瞻性观察研究,2013年5月至2018年6月纳入436例连续肺栓塞患者。
  • 所有患者检测蛋白C、蛋白S、抗凝血酶III、因子V Leiden和凝血酶原G20210A突变。
  • 中位随访时间约800天(范围11-1872天)。

主要发现

  • 436例中31例(7.1%)诊断先天性易栓症。
  • 蛋白C缺陷12例(2.8%),蛋白S缺陷13例(3.0%),抗凝血酶III缺陷5例(1.1%),因子V Leiden 1例(0.2%)。
  • 首次发作年龄≤50岁的比值比为5.43(95%CI 2.35-13.52,P<.001)。
  • 男性的比值比为2.67(95%CI 1.15-6.78,P=.03)。
  • 有无危险因素的肺栓塞患者间先天性易栓症患病率无统计学显著差异(P=.58)。

临床怎么用

  • 对年轻(≤50岁)男性肺栓塞患者可考虑筛查先天性易栓症。
  • 先天性易栓症的存在不改变抗凝治疗下对复发或死亡风险的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence and distribution of congenital thrombophilia is still unclear in patients with pulmonary embolism (PE). We aimed to determine the prevalence and clinical characteristics of congenital thrombophilia in PE patients and their subsequent outcomes. A prospective observational study was conducted from May 2013 to June 2018. A total of 436 consecutive patients with PE were enrolled. All patients were tested for protein C, protein S, antithrombin III (ATIII), factor V Leiden, and prothrombin G20210A mutations. The median follow-up duration was ∼800 days (range, 11-1872 days). Congenital thrombophilia was diagnosed in 31 of 436 (7.1%) patients; 12 patients had protein C deficiency (2.8%), 13 had protein S deficiency (3.0%), 5 had ATIII deficiency (1.1%), and 1 had (0.2%) factor V Leiden. Age ≤50 years at the first episode (odds ratio [OR], 5.43; 95% confidence interval [CI], 2.35-13.52; P < .001) and male sex (OR, 2.67; 95% CI, 1.15-6.78; P = .03) were 2 independent predictors of congenital thrombophilia in PE patients. There was no statistically significant difference in the prevalence of congenital thrombophilia between PE patients with and without risk factors (P = .58). We also found no significant difference in the risk of having a composite outcome of death or recurrent venous thromboembolism between patients with and without congenital thrombophilia (hazard ratio, 0.18; 95% CI, 0.02-5.69; P = .08). These results suggest that age and male sex are independently associated with the occurrence of congenital thrombophilia in PE patients but that congenital thrombophilia is not associated with the risk of recurrence or death with anticoagulation therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lian TY, Lu D, Yan XX, et al. Association between congenital thrombophilia and outcomes in pulmonary embolism patients. Blood Adv. 2020. PMID: 33275768. doi:10.1182/bloodadvances.2020002955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。